If the WHO truly wanted greater differential pricing in developing countries it would support diminishing government intervention and the strengthening of intellectual property rights. That would create the kind of rule-based competition that truly drives companies to expand market share through price incentives. The WHO would better serve the health of the world's people by improving its own performance in the areas where it could make a difference, rather than trying to re-arrange global pharmaceutical markets.
